Aservo Equihaler

Aservo EquiHaler 343 micrograms/actuation inhalation solution for horses

Clear, colourless to yellowish Inhalation solution.
Each actuation (ex nostril adapter) contains:
Active substance: Ciclesonide (343 micrograms)
Excipients: Ethanol (7.9 mg), Hydrochloric acid, Water, purified

Target species: Horses
For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction– (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)).

Inhalation use.
The number of actuations to be administered is the same for all horses. The total treatment duration is 10 days:
- Day 1 to 5:
8 actuations (corresponding to 2,744 µg ciclesonide) administered twice daily approximately 12 h apart
- Day 6 to 10:
12 actuations (corresponding to 4,116 µg ciclesonide) administered once daily approximately 24 h apart.
The onset of clinical improvement may take several days. The 10 days treatment schedule should normally be completed. In case of any concerns related to the treatment the responsible veterinarian should be consulted.
The Aservo EquiHaler contains sufficient inhalation solution for one horse for the entire treatment duration of the 10 days and an additional amount covering priming and potential losses during administration.

Contraindications
Do not use in known cases of hypersensitivity to the active substance, to corticosteroids or to any of the excipients.
Special warnings for each target species
Special care should be taken when administering the veterinary medicinal product. To ensure an efficacious administration, the breath indicator in the chamber wall of the nostril adapter needs to be observed: when the horse inhales, the membrane of the breath indicator curves inwards. During exhalation, the membrane of the breath indicator curves outwards. The spray should be released at the beginning of inhalation, i.e. when the breath indicator starts curving into the chamber. If the movement of the breath indicator cannot be observed, assure the correct positioning of the nostril adapter. If movement of the breath indicator is still not visible or the movement is too rapid, the product should not be administered.
Efficacy of the product has not been established in horses with acute exacerbations (<14 days duration) of clinical signs.

Aservo EquiHaler 343 micrograms/actuation inhalation solution for horses

Clear, colourless to yellowish Inhalation solution.
Each actuation (ex nostril adapter) contains:
Active substance: Ciclesonide (343 micrograms)
Excipients: Ethanol (7.9 mg), Hydrochloric acid, Water, purified

Target species: Horses
For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction– (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)).

Inhalation use.
The number of actuations to be administered is the same for all horses. The total treatment duration is 10 days:
- Day 1 to 5:
8 actuations (corresponding to 2,744 µg ciclesonide) administered twice daily approximately 12 h apart
- Day 6 to 10:
12 actuations (corresponding to 4,116 µg ciclesonide) administered once daily approximately 24 h apart.
The onset of clinical improvement may take several days. The 10 days treatment schedule should normally be completed. In case of any concerns related to the treatment the responsible veterinarian should be consulted.
The Aservo EquiHaler contains sufficient inhalation solution for one horse for the entire treatment duration of the 10 days and an additional amount covering priming and potential losses during administration.

Contraindications
Do not use in known cases of hypersensitivity to the active substance, to corticosteroids or to any of the excipients.
Special warnings for each target species
Special care should be taken when administering the veterinary medicinal product. To ensure an efficacious administration, the breath indicator in the chamber wall of the nostril adapter needs to be observed: when the horse inhales, the membrane of the breath indicator curves inwards. During exhalation, the membrane of the breath indicator curves outwards. The spray should be released at the beginning of inhalation, i.e. when the breath indicator starts curving into the chamber. If the movement of the breath indicator cannot be observed, assure the correct positioning of the nostril adapter. If movement of the breath indicator is still not visible or the movement is too rapid, the product should not be administered.
Efficacy of the product has not been established in horses with acute exacerbations (<14 days duration) of clinical signs.